rCsCP ameliorated colitis mainly through activating TLRs and other related innate immunity, up-regulating the secretion of Th2/Treg related cytokines (e.g., IL-10, IL-4 and IL-13) and down-regulating the expression of inflammatory cytokines (e.g., IL-12b, IL-23r, IL-7 and IL-17A), thereby restricting the transformation of Th1/Th17 cells. Here, IL10 is linked to colitis.